Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson's disease

Journal of the Neurological Sciences

Volumn 318, Issue 1-2, 2012, Pages 90-93

  Santos García, Diego ^a   Prieto Formoso, María ^a   De La Fuente Fernández, Raúl ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

Adherence; Compliance; Dopamine agonist; Morisky Green test; Parkinson's disease

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CARBIDOPA; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DRUG DOSE INCREASE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT COMPLIANCE;

EID: 84861605756     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.03.018     Document Type: Article

References (30)

1. K.A. Grosset, I. Bone, and D.G. Grosset Suboptimal medication adherence in Parkinson's disease Mov Disord 19 2004 513 517
2. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
3. D. Grosset, A. Antonini, M. Canesi, G. Pezzoli, A. Lees, and K. Shaw Adherence to antiparkinson medication in a multicenter European study Mov Disord 24 2009 826 832
4. F. Valldeoriola, C. Coronell, C. Pont, M.T. Buongiorno, A. Cámara, and C. Gaig Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study Eur J Neurol 18 2011 98 987
5. M.Z. Vitolins, C.S. Rand, S.R. Rapp, P.M. Ribisl, and M.A. Sevick Measuring adherence to behavioural and medical interventions Control Clin Trials 21 2000 188S 194S
6. D.E. Morisky, L.W. Green, and D.M. Levine Concurrent and predictive validity of a self-reported measure of medication adherence Med Care 24 1986 67 74
7. S.E. Daniel, and A.J. Lees Parkinson's Disease Society Brain Bank, London: overview and research J Neural Transm Suppl 39 1993 165 172
8. D.W. Hosmer, and S. Lemeshow Applied logistic regression 1989 John Wiley & Sons New York
9. K.L. Davis, H.M. Edin, and J.K. Allen Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data Mov Disord 25 2010 474 480
10. A.S. Kulkarni, R. Balkrishnan, R.T. Anderson, H.M. Edin, J. Kirsch, and M.A. Stacy Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease Mov Disord 23 2008 359 365
11. M.L. Tarrants, M.F. Denarié, J. Castelli-Haley, J. Millard, and D. Zhang Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence Am J Geriatr Pharmacother 8 2010 374 383
12. K.A. Grosset, J.L. Reid, and D.G. Grosset Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 2005 1397 1404
13. K.D. Burney, K. Krishnan, M.T. Ruffin, D. Zhang, and D.E. Brenner Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-reporting and microelectronic monitoring Arch Fam Med 5 1996 297 300
14. H. Liu, C.E. Golin, L.G. Miller, R.D. Hayes, C.K. Beck, and S. Sanandaji A comparison study of multiple measures of adherence to HIV protease inhibitors Ann Intern Med 134 2001 968 977
15. P. Rudd, J. Ramesh, C. Bryant-Kosling, and D. Guerrero Gaps in cardiovascular medication taking J Gen Intern Med 8 1993 659 666
16. R.J. Botelho Home assessment of adherence to long-term medication regimen adherence in clinical trials and clinical practice Clin Ther 21 1999 1074 1090
17. J.A. Cramer, R.H. Mattson, M.L. Prevey, R.D. Scheyer, and V.L. Ouellette How often is medication taken as prescribed? JAMA 261 1989 3273 3277
18. K.C. Farmer Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice Clin Ther 21 1999 1074 1090
19. D.K. Pauler, K.B. Gower, P.J. Goodman, J.J. Crowley, and I.M. Thompson Biomarker-based methods for determining noncompliance in a prevention trial Control Clin Trials 23 2002 675 685
20. J. Urquhart Role of patients compliance in clinical pharmacokinetics. A review of recent research Clin Pharmacokinet 27 1994 202 215
21. L.G. Copeland, J. Dutton, N.B. Roberts, and J.R. Playfer Routine outpatient l-dopa monitoring in elderly patients with Parkinson's disease Age Ageing 23 1994 138 141
22. N.A. Leopold, M. Polansky, and M.R. Hurka Drug adherence in Parkinson's disease Mov Disord 19 2004 513 517
23. K.A. Grosset, I. Bone, J.L. Reid, and D. Grosset Measuring therapy adherence in Parkinson's disease: a comparison of methods J Neurol Neurosurg Psychiatry 77 2006 249 251
24. B.J. Stephenson, B.H. Rowe, R.B. Haynes, W.M. Macharia, and G. Leon The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 269 1993 2779 2781
25. J.J. Elm, C. Kamp, B.C. Tilley, P. Guimaraes, D. Fraser, and P. Deppen NINDS NET-PD investigators and coordinators. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience Mov Disord 22 2007 822 827
26. NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology 66 2006 664 671
27. NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease Neurology 68 2007 20 28
28. J.A. Cramer A systematic review of adherence with medications for diabetes Diabetes Care 27 2004 1218 1224
29. A. Richter, S.E. Anton, P. Koch, and S.L. Dennett The impact of reducing dose frequency on health outcomes Clin Ther 25 2003 2307 2335
30. A. Schnitzler, K.W. Leffers, and H.J. Häck High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease Parkinsonism Relat Disord 16 2010 513 516